Aptar CSP Technologies,has announced the launch of a ‘first-of-its-kind’ active packaging product. The new technology utilizes the company’s patented 3-phase Activ-Polymer platform within its Activ-Film product configuration, it says.
The company added the combined oxygen scavenging and moisture adsorption capability to it’s Activ-Film product to provide customers with a fully integrated solution for drug products that are sensitive to both moisture and oxidation.
The product builds on the recent USA Food & Drug Administration’s approval of an HIV prevention medicine, expected to launch in Q1 2020. This utilizes the company’s Activ-Blister packaging solution to provide moisture adsorption and drug product stability.
According to Aptar CSP, this unique proprietary formulation provides unparalleled dual protection in various packaging configurations, such as Activ-Blister, and broad application fields ranging from oral solid dose and transdermal to diagnostics and probiotics.
“This is an important milestone as it continues to expand the capabilities of the 3-phase Activ-Polymer platform technology, to accelerate and de-risk the product development process, providing solutions that improve and save patients’ lives,” said Badre Hammond, VP of commercial operations, Aptar CSP Technologies. “This technology can help reduce packaging complexity while providing a custom solution to stability concerns, enabling pharmaceutical companies to enhance drug stability and support speed-to-market.”
The 3-phase Activ-Polymer platform technology offers customized active packaging solutions designed to meet the drug developer’s specific formulation as well as provide a broad spectrum of drug-specific protection, including aroma emitting, volatile organic compounds (VOCs) scavenging, and anti-microbial scavenging, according to Aptar CSP.
